Douglas Laird
About
Douglas Laird is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Douglas Laird has authored 22 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Douglas Laird's work include PARP inhibition in cancer therapy (13 papers), Prostate Cancer Treatment and Research (10 papers) and Cancer Genomics and Diagnostics (6 papers). Douglas Laird is often cited by papers focused on PARP inhibition in cancer therapy (13 papers), Prostate Cancer Treatment and Research (10 papers) and Cancer Genomics and Diagnostics (6 papers). Douglas Laird collaborates with scholars based in United States, Italy and France. Douglas Laird's co-authors include Shoucheng Ning, Susan J. Knox, Julie M. Cherrington, Nizar M. Tannir, Cheryl L. Walker, Christopher G. Wood, Erinn B. Rankin, Zhiyong Ding, Priya Rao and Amato J. Giaccia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.
In The Last Decade
Douglas Laird
19 papers receiving 459 citations
Peers
Douglas Laird
Amy E. Hanna United States
Shunli Peng China
Huili Chu China
Huawei Zou China
Inés López Spain
Jinjia Chang China
Suhong Xie China
Vincenzo Ricci Italy
Maria Apicella Italy
K. Papadopoulos United States
Citations per year, relative to Douglas Laird Douglas Laird (= 1×)
peers
Amy E. Hanna
Countries citing papers authored by Douglas Laird
Since
Specialization
Citations
This map shows the geographic impact of Douglas Laird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Laird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Laird more than expected).
Fields of papers citing papers by Douglas Laird
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Douglas Laird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Laird. The network helps show where Douglas Laird may publish in the future.
Co-authorship network of co-authors of Douglas Laird
This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Laird. A scholar is included among the top collaborators of Douglas Laird based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Laird. Douglas Laird is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fizazi, Karim, Arun Azad, Nobuaki Matsubara, et al.. (2025). Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.. Journal of Clinical Oncology. 43(5_suppl).
2.
Fizazi, Karim, Nobuaki Matsubara, Douglas Laird, et al.. (2025). Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2.. Journal of Clinical Oncology. 43(16_suppl). 5019–5019.
3.
Azad, Arun, Karim Fizazi, Douglas Laird, et al.. (2024). Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5020–5020.
4.
Azad, Arun, André P. Fay, Cezary Szczylik, et al.. (2024). 1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study. Annals of Oncology. 35. S987–S988.
5.
Fizazi, Karim, Whijae Roh, Arun Azad, et al.. (2024). Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5021–5021.
6.
Yip, Steven, Karim Fizazi, Douglas Laird, et al.. (2024). Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5023–5023.
7.
Fizazi, Karim, Nobuaki Matsubara, Douglas Laird, et al.. (2024). Exploratory analyses of homologous recombination repair (HRR) gene subgroups and potential associations with secondary efficacy endpoints in the HRR-deficient population from TALAPRO-2.. Journal of Clinical Oncology. 42(4_suppl). 178–178.
8.
Castro, Elena, Douglas Laird, Shuang G. Zhao, et al.. (2023). 1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1. Annals of Oncology. 34. S983–S984.
9.
Azad, Arun, Karim Fizazi, Nobuaki Matsubara, et al.. (2023). Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(16_suppl). 5056–5056.
10.
Bono, Johann S. de, Douglas Laird, Karim Fizazi, et al.. (2022). 1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit. Annals of Oncology. 33. S1167–S1167.
11.
Dorff, Tanya B., Karim Fizazi, Douglas Laird, et al.. (2022). TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity.. Journal of Clinical Oncology. 40(6_suppl). 157–157.
12.
Telli, Melinda L., Jennifer K. Litton, J. Thaddeus Beck, et al.. (2021). Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.. Journal of Clinical Oncology. 39(15_suppl). 554–554.
13.
Litton, Jennifer K., Douglas Laird, Hope S. Rugo, et al.. (2020). Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).. Journal of Clinical Oncology. 38(15_suppl). 1018–1018.
14.
Gökbuget, Nicola, Anjali S. Advani, Matthias Stelljes, et al.. (2018). Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.. Journal of Clinical Oncology. 36(15_suppl). 7013–7013.
15.
Chen, Robert W., Stephen M. Ansell, Pier Luigi Zinzani, et al.. (2017). Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology. 35(15_suppl). TPS7575–TPS7575.
16.
Zhou, Lijun, Xian-De Liu, Mingli Sun, et al.. (2015). Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 35(21). 2687–2697.
17.
Soo, Ross A., Evelyn McKeegan, Choon Hua Thng, et al.. (2008). The effect of varying doses of ABT-869 on biomarkers of angiogenesis and their correlation with pharmacodynamic outcome. Journal of Clinical Oncology. 26(15_suppl). 14535–14535.
18.
Papadopoulos, Kyriakos P., B. Markman, Josep Tabernero, et al.. (2008). A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3510–3510.
19.
Rosen, Lee S., Isett Laux, Melissa Dinolfo, et al.. (2008). A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. Journal of Clinical Oncology. 26(15_suppl). 14585–14585.
20.
Ning, Shoucheng, Douglas Laird, Julie M. Cherrington, & Susan J. Knox. (2002). The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation. Radiation Research. 157(1). 45–51.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Amy E. Hanna Breakdown of academic impact, for papers by Shunli Peng Breakdown of academic impact, for papers by Huili Chu Breakdown of academic impact, for papers by Huawei Zou Breakdown of academic impact, for papers by Inés López Breakdown of academic impact, for papers by Jinjia Chang Breakdown of academic impact, for papers by Suhong Xie Breakdown of academic impact, for papers by Vincenzo Ricci Breakdown of academic impact, for papers by Maria Apicella Breakdown of academic impact, for papers by K. Papadopoulos